- Home
- A-Z Publications
- Current Cancer Drug Targets
- Previous Issues
- Volume 22, Issue 9, 2022
Current Cancer Drug Targets - Volume 22, Issue 9, 2022
Volume 22, Issue 9, 2022
-
-
Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications
Background: Worldwide, gastric cancer is ranked the fifth malignancy in incidence and the third malignancy in mortality. Gastric cancer causes an altered metabolism that can be therapeutically exploited. Objective: The objective of this study is to provide an overview of the significant metabolic alterations caused by gastric cancer and propose a blockade. Methods: A comprehensive and up-to-date review of descriptive Read More
-
-
-
The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention
More LessBackground: Urolithin A is the metabolite of natural polyphenol ellagic acid and ellagitannins generated by gut microbiota. Urolithin A is better absorbed in the gastrointestinal tract than its parent substances. Thus, the variable effects of ellagitannin-reach food (like pomegranate fruit, walnuts, tea, and others) on people's health might be linked with the differences in individual microbiota content. Urolithin A possesses v Read More
-
-
-
Biology, Significance and Immune Signaling of Mucin 1 in Hepatocellular Carcinoma
Authors: Ayana R. Kumar, Aswathy R. Devan, Bhagyalakshmi Nair, Reshma R. Nair and Lekshmi R. NathMucin 1 (MUC 1) is a highly glycosylated tumor-associated antigen (TAA) overexpressed in hepatocellular carcinoma (HCC). This protein plays a critical role in various immune-mediated signaling pathways at its transcriptional and post-transcriptional levels, leading to immune evasion and metastasis in HCC. HCC cells maintain an immune-suppressive environment with the help of immunesuppressive tumor-associated antig Read More
-
-
-
Dietary Flavonoids with Catechol Moiety Inhibit Anticancer Action of Bortezomib: What about the other Boronic Acid-based Drugs?
By Katrin SakApproval of the first boronic acid group-containing drug, bortezomib, in 2003 for the treatment of multiple myeloma sparked an increased interest of medicinal chemists in boronic acidbased therapeutics. As a result, another boronic acid moiety-harboring medication, ixazomib, was approved in 2015 as a second-generation proteasome inhibitor for multiple myeloma; and dutogliptin is under clinical investigation in combination th Read More
-
-
-
Autophagy in Cancer Cell Transformation: A Potential Novel Therapeutic Strategy
More LessBasal autophagy plays a crucial role in maintaining intracellular homeostasis and prevents the cell from escaping the cell cycle regulation mechanisms and being cancerous. Mitophagy and nucleophagy are essential for cell health. Autophagy plays a pivotal role in cancer cell transformation, where upregulated precancerous autophagy induces apoptosis. Impaired autophagy has been shown to upregulate can Read More
-
-
-
PBX1 Participates in Estrogen-mediated Bladder Cancer Progression and Chemo-resistance Affecting Estrogen Receptors
Authors: Yang Zhao, Jizhong Che, Aimin Tian, Gang Zhang, Yankai Xu, Shuhang Li, Songlin Liu and Yinxu WanBackground: Bladder cancer (BCa) is a common cancer associated with high morbidity and mortality worldwide. Pre-B-cell leukemia transcription factor 1 (PBX1) has been reported to be involved in tumor progression. Objective: The aim of the study was to explore the specific role of PBX1 in BCa and its underlying mechanisms. Methods: The relative expressions of PBX1 in muscle-invasive BCa tissues and cell lines were analyz Read More
-
-
-
Inhibitor of Growth 4 (ING4) Plays a Tumor-repressing Role in Oral Squamous Cell Carcinoma via Nuclear Factor Kappa-B (NF-kB)/DNA Methyltransferase 1 (DNMT1) Axis-mediated Regulation of Aldehyde Dehydrogenase 1A2 (ALDH1A2)
Authors: Zhi Cui, Shiqun Sun, Jia Li, Jianing Li, Tong Sha, Jie He and Linjing ZuoBackground: Inhibitor of growth 4 (ING4) level was reported to be decreased in head and neck squamous cell carcinoma (HNSC) tissue, however, it is unknown whether and how ING4 participates in regulating the development of oral squamous cell carcinoma (OSCC). Objective: This study aimed to investigate the role and mechanism of ING4 in OSCC. Methods: ING4 was forced to up- or down-regulated in two OSCC cell lines, and i Read More
-
Volumes & issues
-
Volume 25 (2025)
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
-
Volume 5 (2005)
-
Volume 4 (2004)
-
Volume 3 (2003)
-
Volume 2 (2002)
-
Volume 1 (2001)
Most Read This Month
Article
content/journals/ccdt
Journal
10
5
false
en
